Abstract

Tumor necrosis factor-α-induced protein 8 (TNFAIP8) expression has been linked to tumor progression in various cancer types, but the detailed mechanisms of TNFAIP8 are not fully elucidated. Here we define the role of TNFAIP8 in early events associated with development of hepatocellular carcinoma (HCC). Increased TNFAIP8 levels in HCC cells enhanced cell survival by blocking apoptosis, rendering HCC cells more resistant to the anticancer drugs, sorafenib and regorafenib. TNFAIP8 also induced autophagy and steatosis in liver cancer cells. Consistent with these observations, TNFAIP8 blocked AKT/mTOR signaling and showed direct interaction with ATG3-ATG7 proteins. TNFAIP8 also exhibited binding with fatty acids and modulated expression of lipid/fatty-acid metabolizing enzymes. Chronic feeding of mice with alcohol increased hepatic levels of TNFAIP8, autophagy, and steatosis but not in high-fat-fed obese mice. Similarly, higher TNFAIP8 expression was associated with steatotic livers of human patients with a history of alcohol use but not in steatotic patients with no history of alcohol use. Our data indicate a novel role of TNFAIP8 in modulation of drug resistance, autophagy, and hepatic steatosis, all key early events in HCC progression.

Details

Title
TNFAIP8 regulates autophagy, cell steatosis, and promotes hepatocellular carcinoma cell proliferation
Author
Niture Suryakant 1 ; Gyamfi, Maxwell A 1 ; Lin, Minghui 2 ; Chimeh Uchechukwu 1 ; Dong Xialan 3 ; Zheng Weifan 3 ; Moore, John 1 ; Kumar, Deepak 4   VIAFID ORCID Logo 

 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703) 
 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703); Ningxia Medical University, Ningxia Hui Autonomous Region, Yinchuan, China (GRID:grid.412194.b) (ISNI:0000 0004 1761 9803) 
 North Carolina Central University Durham, Department of Pharmaceutical Sciences, Bio-manufacturing Research Institute and Technology Enterprise (BRITE), Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703) 
 North Carolina Central University Durham, Julius L. Chambers Biomedical Biotechnology Research Institute, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703); North Carolina Central University Durham, Department of Pharmaceutical Sciences, Durham, USA (GRID:grid.261038.e) (ISNI:0000000122955703) 
Publication year
2020
Publication date
Mar 2020
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2375486268
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.